Y MAbs Valuation
| YMAB Stock | USD 11.92 0.04 0.34% |
At this time, the entity appears to be overvalued. Y mAbs Therapeutics maintains a prevalent Real Value of $11.22 per share. The last-minute price of the entity is $11.92. Our model calculates the value of Y mAbs Therapeutics from reviewing the entity fundamentals such as Profit Margin of (0.28) %, current valuation of 466.84 M, and Return On Asset of -0.12 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Y MAbs' valuation include:
Price Book 5.7762 | Enterprise Value 466.8 M | Enterprise Value Ebitda (0.43) | Price Sales 6.3142 | Forward PE 119.0476 |
Overvalued
Today
Please note that Y MAbs' price fluctuation is somewhat reliable at this time. Calculation of the real value of Y mAbs Therapeutics is based on 3 months time horizon. Increasing Y MAbs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Y MAbs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of YMAB Stock. However, Y MAbs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.92 | Real 11.22 | Target 12.43 | Hype 12.21 | Naive 12.7 |
The real value of YMAB Stock, also known as its intrinsic value, is the underlying worth of Y mAbs Therapeutics Company, which is reflected in its stock price. It is based on Y MAbs' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Y MAbs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Y mAbs Therapeutics helps investors to forecast how YMAB stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Y MAbs more accurately as focusing exclusively on Y MAbs' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Y MAbs' intrinsic value based on its ongoing forecasts of Y MAbs' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Y MAbs' closest peers. If more than one evaluation category is relevant for Y MAbs we suggest using both methods to arrive at a better estimate.
Y MAbs Cash |
|
YMAB Valuation Trend
Comparing Y MAbs' enterprise value against its market capitalization is a good way to estimate the value of Y mAbs Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
YMAB Revenue by Product
Y MAbs Total Value Analysis
Y mAbs Therapeutics is at this time forecasted to have valuation of 466.84 M with market capitalization of 533.89 M, debt of 1.42 M, and cash on hands of 133.66 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Y MAbs fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
466.84 M | 533.89 M | 1.42 M | 133.66 M |
Y MAbs Investor Information
About 12.0% of the company outstanding shares are owned by insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.04. Y mAbs Therapeutics recorded a loss per share of 0.54. The entity had not issued any dividends in recent years. Based on the key indicators related to Y MAbs' liquidity, profitability, solvency, and operating efficiency, Y mAbs Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Y MAbs Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Y MAbs has an asset utilization ratio of 66.33 percent. This suggests that the Company is making $0.66 for each dollar of assets. An increasing asset utilization means that Y mAbs Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Y MAbs Ownership Allocation
Y mAbs Therapeutics retains a total of 44.79 Million outstanding shares. The majority of Y MAbs outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Y mAbs Therapeutics to benefit from reduced commissions. Therefore, other corporate entities are subject to a different set of regulations than regular investors in Y mAbs Therapeutics. Please pay attention to any change in the institutional holdings of Y mAbs Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the entity is less than the current market value, you may not be able to make money on it.Y MAbs Profitability Analysis
The company reported the previous year's revenue of 84.82 M. Net Loss for the year was (21.43 M) with profit before overhead, payroll, taxes, and interest of 57.7 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Y MAbs' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Y MAbs and how it compares across the competition.
About Y MAbs Valuation
The stock valuation mechanism determines Y MAbs' current worth on a weekly basis. Our valuation model uses a comparative analysis of Y MAbs. We calculate exposure to Y MAbs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Y MAbs's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 73.4 M | 77.1 M | |
| Pretax Profit Margin | (0.25) | (0.26) | |
| Operating Profit Margin | (0.30) | (0.32) | |
| Net Loss | (0.25) | (0.27) | |
| Gross Profit Margin | 0.87 | 0.98 |
Y MAbs Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 43.6 M | |
| Forward Price Earnings | 119.0476 |
Y MAbs Current Valuation Indicators
Valuation refers to the process of determining the present value of Y mAbs Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value YMAB we look at many different elements of the entity such as YMAB's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Y MAbs, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Y MAbs' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Y MAbs' worth.Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |